Acrivon Therapeutics (ACRV) CDO reports 403-share tax withholding

Acrivon Therapeutics, Inc. reported an insider equity transaction by its Chief Development Officer.

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. reported an insider equity transaction by its Chief Development Officer. On 11/14/2025, 403 shares of Acrivon Therapeutics common stock were disposed of at a price of $2.24 per share. The filing explains that these shares were withheld by the company to satisfy mandatory tax withholding upon the vesting of restricted stock units, rather than being an open-market sale. Following this withholding event, the officer beneficially owned 15,283 shares of Acrivon Therapeutics common stock, held directly.

Insider Trade Summary

Exercise Price or Tax Liability: 403 shares

Exercise Price or Tax Liability 1 txn

Insider Gamelin Erick

Role Chief Development Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	403	$2.24	$902.72

Holdings After Transaction: Common Stock — 15,283 shares (Direct)

Footnotes (1)

1. F1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Acrivon Therapeutics (ACRV) disclose in this Form 4?

The company disclosed that its Chief Development Officer had 403 shares of Acrivon Therapeutics common stock withheld on 11/14/2025 at $2.24 per share to cover mandatory tax withholding upon the vesting of restricted stock units.

Who is the reporting person in this Acrivon Therapeutics (ACRV) Form 4 filing?

The reporting person is an officer of Acrivon Therapeutics, Inc., serving as the Chief Development Officer of the company.

How many Acrivon Therapeutics (ACRV) shares does the officer own after the reported transaction?

After the reported tax withholding transaction, the officer beneficially owns 15,283 shares of Acrivon Therapeutics common stock, held directly.

What was the nature of the 403 ACRV shares disposed of in the Form 4?

The 403 shares were withheld by the issuer to satisfy the mandatory tax withholding requirement when restricted stock units vested, as noted in the explanation of responses.

Was this ACRV Form 4 transaction an open-market sale by the officer?

No. The Form 4 states that the shares were withheld by Acrivon Therapeutics to meet mandatory tax withholding upon RSU vesting, rather than sold in the open market.

What is the transaction code used in the ACRV Form 4, and what does it represent?

The transaction code is F, which in this context represents shares withheld by the issuer to pay tax obligations upon the vesting of equity awards such as restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/18/2025 - 04:30 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gamelin Erick

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/14/2025		F(1)		403	D	$2.24	15,283	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

	/s/ Adam D. Levy, Attorney-in-Fact	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.